Table 3.

Multivariate analysis of prognosis in patients with HDCA/CY/TBI compared with CY/TBI

Variables		Overall mortality				Tumor-related mortality				NRM
		HR		(95 % CI)	p	HR		(95 % CI)	p	HR		(95 % CI)	p
Conditioning	CY/TBI	(Reference)				(Reference)				(Reference)
	HDCA/CY/TBI	1.14	(0.96–1.34)		0.13	0.90		(0.72–1.12)	0.34	1.48		(1.15–1.91)	<0.01*
Other variables
Age	≤49	(Reference)				(Reference)				(Reference)
	≥50	1.86	(1.57–2.20)		<0.01*	1.31		(1.02–1.68)	0.03*	2.04		(1.60–2.61)	<0.01*
PS	0–1	(Reference)				(Reference)				(Reference)
	≥2	1.42	(1.09–1.85)		<0.01*	1.73		(1.25–2.39)	<0.01*	0.71		(0.41–1.23)	0.22
CMV sero-status	Negative	(Reference)				(Reference)				(Reference)
	Positive	1.12	(0.93–1.34)		0.23	1.29		(1.00–1.65)	0.05*	0.91		(0.70–1.18)	0.47
Diagnosis	AML	(Reference)				(Reference)				(Reference)
	MDS	0.40	(0.32–0.51)		<0.01*	0.18		(0.12–0.27)	<0.01*	1.18		(0.87–1.59)	0.28
Disease risk	Standard	(Reference)				(Reference)				(Reference)
	High	2.53	(2.18–2.93)		<0.01*	3.98		(3.26–4.85)	<0.01*	0.97		(0.77–1.23)	0.82
Days from diagnosis to HCT	≤240	(Reference)				(Reference)				(Reference)
	≥241	0.88	(0.76–1.01)		0.07	0.80		(0.66–0.97)	0.02*	0.98		(0.79–1.22)	0.89
HLA mismatch	Matched	(Reference)				(Reference)				(Reference)
	Mismatched	1.25	(1.08–1.44)		<0.01*	0.90		(0.73–1.10)	0.30	1.60		(1.29–1.99)	<0.01*
Sex mismatch	Matched	(Reference)				(Reference)				(Reference)
	M to F	0.97	(0.81–1.15)		0.70	0.91	(0.72–1.15)		0.44	1.01	(0.77–1.31)		0.97
	F to M	1.12	(0.94–1.33)		0.20	0.94	(0.74–1.20)		0.63	1.28	(0.99–1.65)		0.07
Year of HCT	≤2008	(Reference)				(Reference)				(Reference)
	≥2009	0.89	(0.77–1.02)		0.10	0.96	(0.80–1.16)		0.70	0.76	(0.61–0.94)		0.01*

Other abbreviations are explained in Tables 1 and 2

NRM non-relapse mortality

^*Indicates statistically significant